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ABBREVIATIONS
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MMT  methadone maintenance therapy
NAS  neonatal abstinence syndrome
NRT  nicotine replacement therapy
UDS  urine drug screening
Abstract
Objective: To improve awareness and knowledge of problematic 
substance use in pregnancy and to provide evidence-based 
recommendations for the management of this challenging clinical 
issue for all health care providers .
Options: This guideline reviews the use of screening tools, general 
approach to care, and recommendations for clinical management 
of problematic substance use in pregnancy .
Outcomes: Evidence-based recommendations for screening and 
management of problematic substance use during pregnancy 
and lactation .
Evidence: Medline, PubMed, CINAHL, and The Cochrane Library 
were searched for articles published from 1950 using the 
following key words: substance-related disorders, mass 
screening, pregnancy complications, pregnancy, prenatal 
care, cocaine, cannabis, methadone, opioid, tobacco, nicotine, 
solvents, hallucinogens, and amphetamines . Results were 
initially restricted to systematic reviews and randomized 
control trials/controlled clinical trials . A subsequent search for 
observational studies was also conducted because there are 
few RCTs in this field of study . Articles were restricted to human 
studies published in English . Additional articles were located by 
hand searching through article reference lists . Searches were 
updated on a regular basis and incorporated in the guideline 
up to December 2009 . Grey (unpublished) literature was also 
identified through searching the websites of health technology 
assessment and health technology assessment-related agencies, 
clinical practice guideline collections, clinical trial registries, and 
national and international medical specialty societies .
Values: The quality of evidence was rated using the criteria described 
in the Report of the Canadian Task Force on the Preventive 
Health Care . Recommendations for practice were ranked 
according to the method described in that report (Table 1) .
Benefits, harms, and costs: This guideline is intended to increase 
the knowledge and comfort level of health care providers 
caring for pregnant women who have substance use disorders . 
Improved access to health care and assistance with appropriate 
addiction care leads to reduced health care costs and decreased 
maternal and neonatal morbidity and mortality .
Recommendations
1 . All pregnant women and women of childbearing age should be 
screened periodically for alcohol, tobacco, and prescription and 
illicit drug use . (III-A)
2 . When testing for substance use is clinically indicated, urine drug 
screening is the preferred method . (II-2A) Informed consent 
should be obtained from the woman before maternal drug 
toxicology testing is ordered . (III-B)
3 . Policies and legal requirements with respect to drug testing of 
newborns may vary by jurisdiction, and caregivers should be 
familiar with the regulations in their region . (III-A)
4 . Health care providers should employ a flexible approach to the 
care of women who have substance use problems, and they 
should encourage the use of all available community resources . (II-2B)
5 . Women should be counselled about the risks of periconception, 
antepartum, and postpartum drug use . (III-B)
6 . Smoking cessation counselling should be considered as a 
first-line intervention for pregnant smokers . (I-A) Nicotine 
replacement therapy and/or pharmacotherapy can be considered 
if counselling is not successful . (I-A)
7 . Methadone maintenance treatment should be standard of 
care for opioid-dependent women during pregnancy . (II-IA) 
Other slow-release opioid preparations may be considered if 
methadone is not available . (II-2B)
8 . Opioid detoxification should be reserved for selected women 
because of the high risk of relapse to opioids . (II-2B)
9 . Opiate-dependent women should be informed that neonates 
exposed to heroin, prescription opioids, methadone, or 
buprenorphine during pregnancy are monitored closely for 
symptoms and signs of neonatal withdrawal (neonatal abstinence 
syndrome) . (II-2B) Hospitals providing obstetric care should 
develop a protocol for assessment and management of neonates 
exposed to opiates during pregnancy . (III-B)
10 . Antenatal planning for intrapartum and postpartum analgesia 
may be offered for all women in consultation with appropriate 
health care providers . (III-B)
11 . The risks and benefits of breastfeeding should be weighed on an 
individual basis because methadone maintenance therapy is not 
a contraindication to breastfeeding . (II-3B)
INTRODUCTION
Substance use during pregnancy is common. In national prevalence surveys, 14% of  Canadian women reported 
using alcohol during their last pregnancy, and 17% reported 
smoking during pregnancy.1,2 The prevalence of  illicit drug 
use among Canadian women of  childbearing age is less but 
not insignificant. In United States population surveys ~5% 
of  pregnant women reported illicit drug use during the 
preceding month.3 Marijuana remains the most commonly 
used illegal drug, followed by cocaine. Women report 
higher rates than men of  prescription drug use, including 
pain relievers (23.1%), opioid analgesics (2.1%), sleeping 
pills (1.7%), tranquilizers (1.1%), and antidepressants 
(2.1%).2
The use of  alcohol and drugs by pregnant women can result 
in significant maternal, fetal, and neonatal morbidity.4–17 In 
general, pregnant women with substance use disorders are 
less likely to seek prenatal care, and they have higher rates 
of  infectious diseases such as HIV, hepatitis, and other 
sexually transmitted infections.17–19
There are numerous direct and indirect costs of  perinatal 
substance exposure. In 2002, the overall social cost of  
substance abuse in Canada, including burden on health 
care, law enforcement, and loss of  productivity due to 
premature death and ill health, totalled ~$40 billion.20 Data 
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Table 1. Key to evidence statements and grading of recommendations, using the ranking of the Canadian Task Force  
on Preventive Health Care
Quality of evidence assessment* Classification of recommendations†
I:       Evidence obtained from at least one properly randomized  
controlled trial
A .  There is good evidence to recommend the clinical preventive action
II-1:   Evidence from well-designed controlled trials  without    
randomization
B .  There is fair evidence to recommend the clinical preventive action
II-2:   Evidence from well–designed cohort (prospective or   
retrospective) or case–control studies, preferably from   
more than one centre or research group
C .  The existing evidence is conflicting and does not allow to make a 
recommendation for or against use of the clinical preventive action; 
however, other factors may influence decision-making
II-3:   Evidence obtained from comparisons between times or  
places with or without the  intervention . Dramatic results in 
uncontrolled experiments (such as the results of treatment with 
penicillin in the 1940s) could also be included in this category
D .  There is fair evidence to recommend against the clinical preventive action
E .   There is good evidence to recommend against the clinical preventive 
action
III:     Opinions of respected authorities, based on clinical experience, 
descriptive studies, or reports of expert committees
L .   There is insufficient evidence (in quantity or quality) to make 
a recommendation; however, other factors may influence 
decision-making
*The quality of evidence reported in these guidelines has been adapted from The Evaluation of Evidence criteria described in the Canadian Task Force on 
Preventive Health Care .161 
†Recommendations included in these guidelines have been adapted from the Classification of Recommendations criteria described in the The Canadian Task 
Force on Preventive Health Care .161
from American studies have indicated that the increase 
in cost of  neonatal care for infants born to mothers who 
smoke cigarettes is ~$700, and the increase in cost for 
those exposed to cocaine is $5110 per patient.21–23
Because of  the prevalence of  substance use and its clinical 
and economic impact, health care providers need to know 
how to identify and care for the affected patient population. 
Management of  substance use disorders is complicated 
because of  the associated comorbid conditions and 
psychosocial and socioeconomic factors, such as mental 
health problems, poor housing, financial stressors, and lack 
of  supports. Canadian physicians have identified a lack 
of  knowledge and training regarding the effects of  and 
treatments for substance use during pregnancy as another 
barrier to providing care for these patients.24 Perinatal care 
providers have several opportunities during pregnancy to 
identify and assist women who have substance use problems. 
Although most physicians enquire routinely about alcohol, 
tobacco, and other drug use during pregnancy, many 
do not use a specific screening tool and are not making 
referrals to other treatment resources.25–28 As motivation to 
change unhealthy or harmful behaviours is increased during 
pregnancy, it is an ideal time to intervene with women who 
have substance use problems.
This guideline provides a unified approach to care for 
perinatal substance use disorders.
DEFINITIONS
Substance abuse and dependence have well-defined 
criteria based on the DSM-IV guide (Table 2).29 Substance 
dependence is characterized by compulsive drug use, loss 
of  control over use, and physical, social, and psychological 
consequences.30 Physical dependence is characterized 
by tolerance and withdrawal; however, it is not in itself  
sufficient to make a diagnosis of  substance dependence. 
Substance withdrawal consists of  a combination of  drug-
specific symptoms and signs that occur within hours to 
days of  stopping drug use (Table 3).
IDENTIFICATION OF SUBSTANCE-RELATED 
DISORDERS IN PREGNANCY
Screening and Assessment
All pregnant women regardless of  socioeconomic status 
should be asked about past and current alcohol, nicotine, 
and illicit and prescribed drug use. A high index of  suspicion 
for potential substance use during pregnancy is required in 
various clinical situations.31 There is no optimal screening 
tool for identifying substance use in pregnancy. Maternal 
interview using open-ended, non-judgemental questioning 
is more likely to elicit disclosure of  perinatal substance 
use.31,32 Health care providers should develop their own 
level of  comfort and style in asking their patients about this 
sensitive topic. The T-ACE and TWEAK questionnaires 
were developed for screening at-risk perinatal alcohol use 
370  l  APRIL JOGC AVRIL 2011
SOGC CLINICAL PRACTICE GUIDELINE
(Figure 1).33,34 The ALPHA tool incorporates the CAGE 
questionnaire to screen for maternal recreational drug 
use, as well as validated questions to identify associated 
psychosocial risk factors such as family violence or 
postpartum depression (Appendix).35,36 If  the woman 
acknowledges substance use, a more complete assessment 
is then recommended to determine if  there is a history of  
substance abuse or dependence (Figure 2).
Role of Toxicology Testing
Drug toxicology testing is not recommended for universal 
screening (i.e., routine testing of  all women) because it has 
numerous limitations (Figure 3), and it should be considered 
only after a comprehensive assessment if  there is a clinical 
indication.37 If  a woman is concerned about providing 
a sample or is reluctant to do so, clinicians should focus 
on developing a trusting relationship before suggesting 
toxicology testing. Vulnerable women may feel threatened 
if  clinicians wish to gather detailed information through 
drug testing and psychosocial histories.
Urine, hair, and meconium samples are sensitive biological 
markers of  substance use. Urine drug screening can detect 
only recent substance exposure, while neonatal hair and 
meconium testing can document intrauterine use because 
meconium and hair form in the second and third trimester, 
respectively.38–41 By itself, a single positive test result cannot 
be used to diagnose substance dependence. Although 
child protection agencies sometimes request hair analyses, 
neither hair nor meconium is appropriate for routine 
clinical use because of  the high costs and propensity for 
false positive results.
UDS has several clinical indications. Evidence shows that 
the addition of  urine drug testing to the structured maternal 
interview can increase the detection of  problematic 
substance use in pregnancy.42,43 Detection can facilitate 
early intervention, including treatment of  maternal and 
neonatal withdrawal and counselling and referral for long-
term outpatient treatment. For example, an unexpected 
positive UDS result for opioids may prompt an assessment 
for opioid dependence and observation of  the neonate for 
signs of  withdrawal. Ongoing outpatient monitoring with 
UDS is also used to advocate on behalf  of  patients with 
child protection services and to monitor compliance with 
prescribed medications (e.g., opioids).34,38 In addition, it can 
be performed on maternal request.
Informed consent must be obtained and documented in 
the medical record before any maternal drug testing is 
performed (except in life-threatening situations where 
informed consent is impossible).44 If  the mother refuses, 
this should be documented, and testing should not be 
performed. Neonatal toxicology testing may be performed 
without consent of  the parent(s) if  the person requesting 
this testing has a legislative right to make decisions for 
the infant to be tested. However, the mother should be 
informed that the neonate is being tested.34 Once consent 
is obtained, any drug toxicology testing to be performed 
must be ordered by the physician responsible for maternal 
and/or neonatal care.
Recommendations
1. All pregnant women and women of  childbearing age 
should be screened periodically for alcohol, tobacco, 
and prescription and illicit drug use. (III-A)
Table 2. Definitions of substance-related disorders
Substance  
use disorder
 
Definition
Substance 
dependence
A pattern of substance use, leading to 
clinically significant impairment or distress, as 
manifested by ≥ 3 of the following, occurring at 
any time in the same 12-month period:
1 . tolerance
2 . withdrawal
3 . substance taken in larger amounts or over a 
longer period than was intended
4 . persistent desire or unsuccessful efforts to 
cut down or control substance use
5 . a great deal of time spent in activities 
necessary to obtain the substance (e .g ., 
visiting multiple doctors or driving long 
distances), use the substance (e .g ., chain-
smoking), or recover from its effects
6 . important social, occupational, or 
recreational activities given up or reduced 
because of substance use
7 . continued use despite knowledge of harm
Substance abuse A pattern of substance use leading to 
clinically significant impairment or distress, as 
manifested by ≥ 1 of the following, occurring 
within a 12-month period:
1 . recurrent substance use resulting in a 
failure to fulfill major role obligations at work, 
school, or home
2 . recurrent substance use in situations in 
which it is physically hazardous
3 . recurrent substance-related legal problems
4 . persistent or recurrent social or interpersonal 
problems caused or exacerbated by the 
effects of the substance
Tolerance Characterized by a need for markedly 
increased amounts of the substance to 
achieve desired effect or diminished effect with 
continued use of the same amount of  
the substance
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2. When testing for substance use is clinically indicated, 
urine drug screening is the preferred method. (II-2A) 
Informed consent should be obtained from the woman 
before maternal drug toxicology testing is ordered. 
(III-B)
3. Policies and legal requirements with respect to drug 
testing of  newborns may vary by jurisdiction, and 
caregivers should be familiar with the regulations in 
their region. (III-A)
COMPONENTS OF OFFICE MANAGEMENT
Obstetrical care providers need to establish rapport 
with substance-using pregnant women through good 
communication and a willingness to be flexible in providing 
prenatal care and ongoing support. These women face a 
number of  barriers to receiving optimal prenatal care 
(Figure 4).45–48 Flexibility with respect to patient scheduling 
and understanding late arrivals and missed appointments 
are key to engaging these women for prenatal care. Women 
are likely to seek and commit to prenatal care if  health care 
providers are welcoming and non-judgemental, and if  they 
acknowledge the women’s courage and persistence in the 
face of  very difficult personal circumstances. Studies have 
shown that comprehensive care provided at one site is cost-
effective and produces better outcomes for both mother 
and child.9,19,49–58
It is also important to address women’s substance use 
because pregnancy is an ideal time for women to make a 
change. Harm reduction is defined as a program or policy 
designed to reduce the drug-related harm without requiring 
the cessation of  drug use.30 The philosophy of  care for 
women with problematic substance use in pregnancy is 
harm reduction. Components of  this philosophy include 
encouragement of  abstinence or reduction of  use, safe 
use, treatment of  withdrawal symptoms, counselling and/
or pharmacotherapy. Pregnancy may motivate women to 
abstain from or reduce drug use, given the potential effects 
on fetal outcomes.
Pregnant substance-using women are also at increased 
risk of  infectious diseases. Injection drug use remains the 
most dominant mode of  hepatitis C virus acquisition. 
Approximately, 70% to 80% of  HCV-infected patients 
report a history of  current or past injection drug use.59 
HCV-negative women should be advised about ways to 
prevent exposure to HCV. Women should be told not to 
share materials to prepare, inject, or inhale drugs, and that 
they should not engage in higher risk sexual behaviours 
(e.g., unprotected sex with multiple sexual partners or 
unprotected sex with HCV-positive partners). Pregnant 
HCV-infected women have a 5% chance of  transmitting 
the virus to their infants.60 There are no ways to decrease 
the risk of  vertical transmission. Furthermore, mode of  
delivery and breastfeeding do not affect mother-to-infant 
transmission. Procedures that promote mixing of  maternal 
and fetal blood, such as use of  scalp electrodes, should be 
avoided, if  possible. Serology testing of  infants at 12 to 18 
months of  age is recommended to determine HCV status.
The prevalence of  sexually transmitted infections is also 
higher among pregnant women with a history of  substance 
abuse related to high-risk sexual behaviours.61,62 Screening 
for Chlamydia, gonorrhea, syphilis, hepatitis, and HIV 
should be repeated throughout pregnancy if  historical 
factors warrant it.63
There are numerous adverse effects associated with 
prenatal drug exposure (Table 4). These effects may also 
be linked to other factors such as inadequate prenatal care, 
poor social circumstances, and concomitant use of  other 
substances.64,65 Therefore, long-term studies are difficult to 
Table 3. Withdrawal syndromes
Substance Withdrawal symptoms and signs
Nicotine Irritability, restlessness, anxiety, insomnia, fatigue, poor concentration
Marijuana Irritability, insomnia, anorexia, anxiety
Opioids Influenza-like symptoms: myalgias, rhinorrhea, goosebumps, diaphoresis, nausea,  
vomiting, diarrhea
Psychological symptoms: insomnia, anxiety, strong cravings, dysphoria
Obstetrical symptoms: abdominal cramping, uterine irritability
Benzodiazepines Seizures (high dose), anxiety, panic attacks, insomnia, emotional lability
Cocaine/amphetamines Crash phase: fatigue, increased appetite 
Withdrawal dysphoria phase: dysphoria, irritability, insomnia, strong cravings
Inhalants Similar to alcohol withdrawal: tremor, malaise, gastrointestinal symptom
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interpret because effects may be due to these confounders 
and environmental deprivation rather than the drug itself. 
In addition to routine care, patients should be given 
counselling regarding the drug-specific fetal, neonatal, and 
maternal effects of  substance use.
Antenatal fetal surveillance should be based on obstetrical 
indications rather than solely on substance use. Substance 
use during pregnancy has been associated with obstetrical 
complications such as preterm labour, placental abruption, 
and intrauterine growth restriction (Table 4), and these 
adverse effects may lead to an increased risk of  perinatal 
morbidity and mortality. Therefore, the method and 
frequency of  antenatal testing will be determined by the 
presence or absence of  these complications.66
There are two phases to the management of  substance 
use disorders. The first addresses treatment of  withdrawal 
syndromes. Pregnant women who are dependent on alcohol, 
opioids, or high-dose benzodiazepines (> 50 mg daily 
diazepam equivalent) may require medical detoxification 
under the supervision of  a physician (Table 5).30 Women 
who are in withdrawal from other substances, such as 
cocaine or marijuana, may also benefit from a supportive 
admission to a non-medical withdrawal management 
centre, if  available.
T-ACE
T How many drinks does it take to make you feel high? (Tolerance)
A Have people annoyed you by criticizing your drinking?
C Have you felt you ought to cut down on your drinking?
E Have you ever had a drink first thing in the morning to steady your nerves or get rid      
of a hangover? (Eye-opener)
Scoring: T: 2 points if > 3 drinks; A,C,E: 1 point for each yes answer
A total of 2 or more points indicates patient is likely to have an alcohol problem .
TWEAK
T Tolerance
W Have friends or relatives complained about your drinking? (Worried)
E Eye-opener
A Has a friend or family member ever told you about things you said or did while you 
were drinking that you could not remember? (Amnesia or black-out)
K Cut-down
Scoring: T: 2 points if > 3 drinks; W, E, A, K: 1 point for each yes answer
A total of score of 3 or more points indicates patient is at-risk drinking
Figure 1. T-ACE and TWEAK for problematic alcohol use
Complete drug history: name of drug, amount, frequency, duration, route(s), last use, 
injection drug use, sharing needles/paraphernalia, withdrawal symptoms
Stage of change with respect to substance use
• Consequences of drug use: medical, social, personal
• Previous treatment programs, mutual aid groups (e .g ., AA)
Medical history: HIV, Hepatitis B and C, STIs
• Chronic medical conditions (e .g ., chronic pain), medications
Psychiatric history: eating disorders, sexual/physical abuse, mood and 
anxiety disorders
Obstetrical history: cycle regularity, LMP, past obstetrical outcomes and 
complications
Social history: family situation (partner and number of children), custody status, 
housing situation, legal status (current charges and court dates), finances, nutrition, 
child protection agency involvement, child safety concerns
FIFE: feelings, impressions/ideas, functioning, expectations about pregnancy 
and drug use
Figure 2. Assessment for substance-related disorders
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The second phase focuses on relapse prevention by 
encouraging substance abuse treatment and development 
of  a supportive network. Brief  interventions can range 
from simple physician advice to motivation counselling 
sessions consisting of  goal setting, problem solving with 
respect to triggers, and information on potential harms. 
These interventions are effective in reducing alcohol 
use among pregnant women.67,68 Currently, there are no 
research data on the effectiveness of  similar interventions 
for illicit substance use in pregnancy. However, systematic 
reviews have shown that outpatient psychotherapy for 
cannabis dependence is moderately effective at reducing 
substance use in non-pregnant patients.69,70 Therefore, 
physician counselling may also be of  benefit to pregnant 
women. Pharmacological maintenance options are available 
for management of  nicotine and opioid dependence. 
Evidence suggests that enhanced treatment programs for 
opioid dependence that combine methadone maintenance 
therapy, group psychotherapy, and obstetrical care result 
in less overall illicit substance use, improved prenatal care, 
and lower rates of  obstetrical complications.19,52,71–73 Evaluation 
of  comorbid conditions should include screening for 
depression, anxiety, and other mental health disorders, 
domestic violence and abuse, and psychosocial support 
system. Most women in substance abuse treatment 
programs report a past history of  trauma (including physical 
and sexual abuse), and approximately 25% have been 
diagnosed with posttraumatic stress disorder.74–76 Partner 
involvement in prenatal care and addiction treatment 
is critical to recovery.56 A partner’s active drug use has 
been linked to delayed treatment time for women seeking 
care.77,78 Similarly, women with fewer social supports are less 
likely to seek and to remain in treatment.79,80 Appropriate 
referrals may include counselling to deal with pre-existing 
trauma and assistance with other social determinants of  
health (e.g., food and housing). The cornerstone of  care 
of  problematic substance use in pregnant women is harm 
reduction. Components of  this include encouragement 
of  abstinence or reduction of  use, safe use, treatment of  
withdrawal, counselling, and/or pharmacotherapy.
Any health care provider who has a clinical suspicion based 
on history and/or physical examination that a child is or 
may be in need of  protection because of  abuse or neglect 
must make a report to child protection services.81 Health 
care professionals should be aware of  province-specific 
legislation with respect to child welfare and reporting 
responsibilities. Clinicians are not required to report until 
birth, because unborn babies do not have any legal rights, 
but antenatal self-reporting is encouraged to increase 
maternal self-determination, dignity, and stability and 
the establishment of  a treatment plan. However, if  other 
children present in the home are deemed to be at risk, 
earlier referral to child protection is indicated to ensure 
the safety of  these children. Health care professionals 
should advocate on behalf  of  women involved with 
child protection agencies and should encourage a positive 
relationship between mothers and workers. A history of  
substance dependence is not incompatible with ability to 
parent.
Recommendations
4. Health care providers should employ a flexible 
approach to the care of  women who have substance 
use problems, and they should encourage the use of  
all available community resources. (II-2B)
5. Women should be counselled about the risks of  
periconception, antepartum, and postpartum drug 
use. (III-B)
•  Personal factors: shame, stigma, guilt, lack of family support, substance using male partner, fear of losing 
children, concomitant psychosocial issues (e .g ., transportation, child care)
•  Systemic factors: lack of appropriate treatment services for pregnant women, negative attitudes of health 
care providers
Figure 4. Barriers to prenatal care for pregnant substance-using women
•  Women can avoid detection of substances in urine samples through simple measures such as abstaining 
for 1–3 days before testing, drinking lots of water to lower the concentration of the drug in the urine, or 
substituting samples of another person’s urine for their own
•  Alcohol is very hard to detect with laboratory testing (blood and urine sampling) because of its short half-life
•  The amount of drug in a hair sample correlates with degree of drug use (which is not the case with urine 
drug testing); however, a positive finding is not diagnostic of addiction
•  Hair analysis can have false-positive results due to passive exposure to smoked drugs in environment
•  A false positive result can have serious legal and emotional consequences for the mother
Figure 3. Limitations of drug toxicology
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Smoking Cessation Counselling
Smoking cessation interventions are effective in reducing the 
number of  women smoking during pregnancy regardless of  
intensity or provider delivering the intervention.82–87 Lower 
rates of  preterm delivery and low birth weight infants are 
additional benefits of  smoking cessation interventions. 
A variety of  interventions have been studied ranging 
from simple advice to cognitive behavioural strategies for 
quitting smoking. Women also often received pregnancy-
specific self-help materials and telephone counselling to 
support smoking cessation.
These interventions are estimated to be highly cost-effective 
with savings of  US$3 in health-related costs for every 
US$1 spent on smoking cessation for pregnant women.88 
However, brief  interventions are ineffective in preventing 
postpartum relapse to smoking.89
Pharmacotherapy
Controlled trials have failed to demonstrate that nicotine 
replacement therapy increases smoking cessation 
rates, although it may reduce the number of  cigarettes 
smoked.90,91 NRT (gum, lozenge, or patch), combined 
with cognitive behavioural therapy, results in higher quit 
rates during pregnancy than counselling alone.92 The 
safety of  NRT is unknown since the link between NRT 
and congenital anomalies and poor perinatal outcomes is 
uncertain.90,92–96 However, women may be offered NRT if  
they continue to smoke despite counselling and after an 
informed discussion regarding the benefits and risks during 
pregnancy.82,83,97,98 Intermittent dosage NRT preparations 
such as nicotine gum or nasal spray may be preferable to 
the patch, which gives a continuous dose of  nicotine. The 
lowest effective dose of  NRT is advised. If  the patch is 
used, the patient may consider removing it at night. NRT 
should be discontinued if  the woman continues to smoke 
at the same rate.
Table 4. Effects of antenatal substance use
Drug Antenatal complications Neonatal effects Long-term effects
Nicotine • SA 
• PTL, PROM
• Placenta previa and 
placental abruption
• IUGR, LBW
• Increased perinatal mortality
• SIDS
• Childhood asthma
• Behavioural problems
• ADHD
Marijuana • Inconsistent effects • • Neurobehavioural effects: decreased 
self-quieting ability, increased fine tremors 
and startles, increased hand-to-mouth 
activity, sleep pattern changes 
• Disturbed nocturnal sleep
• Behaviour problems: inattention, 
impulsivity and hyperactivity, 
delinquency and externalizing 
problems self-reported depressive and 
anxiety symptoms
Heroin • Premature labour
• IUGR, LBW
• Toxemia
• Antepartum and 
postpartum hemorrhage
• Increased perinatal mortality rate • Increased inattention, hyperactivity 
and behavioural problems
• Difficulty in physical, social, and self-
adjustment and learning processes
Methadone • NAS
• Strabismus
Cocaine • Spontaneous abortion
• PROM, PTL
• IUGR
• Placental abruption
• Congenital anomalies: genitourinary 
malformations
• Transient increase in central and 
autonomic nervous system symptoms and 
signs
• Lower birth weight, length and head 
circumference (dose-dependent)
• Expressive language delays
Amphetamines • Maternal hypertension
• Fetal demise (at any 
gestational age)
• IUGR
• Congenital anomalies:central nervous 
system, cardiovascular, oral clefts, limbs
• Neurobehavioural effects: decreased 
arousal, increased stress and poor quality 
of movement (dose-response relationship)
• Behavioural problems
Hallucinogens  
(MDMA, LSD)
• Congenital anomalies: cardiovascular, 
MSK defects
ADHD: attention-deficit hyperactivity disorder; IUGR: intrauterine growth restriction; LBW: low birth weight; LSD: lysergic acid diethylamide;  
MDMA: 3,4-methylenedioxymethamphetamine; MSK: medullary sponge kidney; PTL: preterm labour; PROM: premature rupture of membranes;  
SA: spontaneous abortion; SIDS: sudden infant death syndrome .
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Buproprion and varenicline are effective in non-pregnant 
populations. There are limited safety data on the use 
of  these medications during pregnancy.82,83,97 To date, 
bupropion has not been associated with malformations 
during pregnancy.83,97,99 Preliminary evidence from a small 
study suggests that bupropion is effective for smoking 
cessation during pregnancy.100 Further research is needed on 
the safety and efficacy of  bupropion and varenicline before 
they can be recommended for routine use in pregnancy.
Recommendation
6. Smoking cessation counselling should be considered 
as a first-line intervention for pregnant smokers. (I-A) 
Nicotine replacement therapy and/or pharmacotherapy 
can be considered if  counselling is not successful. (I-A)
OPIOID DEPENDENCE
Opioid Detoxification
Opioid detoxification is defined as medication-assisted 
withdrawal for opioid-dependent patients. There is good 
evidence that detoxification in the second and third trimesters 
of  pregnancy is not linked to increased adverse perinatal 
events. Recent studies have failed to show any significant 
increased rates of  obstetrical complications following opioid 
detoxification.91,93,94,101 Regardless, opioid detoxification is 
not advisable during pregnancy primarily because of  the 
high rate of  relapse.102–106 Opioid detoxification should be 
performed only after the first trimester and with informed 
consent based on a discussion of  the potential risks and bene-
fits. Methadone maintenance treatment is associated with 
longer adherence to treatment and decreased risk of  relapse 
to opioid use; therefore, the standard of  care for pregnant 
opioid-dependent women is opiate substitution therapy.
Methadone Maintenance Treatment
Currently, methadone maintenance treatment is the standard 
of  care for opioid dependence in pregnancy. Methadone is 
a full opioid agonist that has an increasing effect with higher 
doses. There are numerous benefits of  methadone use 
during pregnancy, including improved prenatal care,12,107–109 
longer gestation,50,110 higher birth weight,111,112 and increased 
rates of  infants discharged home in the care of  their 
mothers.4,12,18,49,101,108,113–118 Although infants of  methadone-
treated women tend to be smaller (lower birth weight, 
length, and head circumference) than drug-free controls, 
studies have shown a catch-up of  growth by 12 months of  
age.118,119 Urgent consultation with an addiction medicine 
specialist should be sought to facilitate rapid access to MMT 
during pregnancy. Close monitoring of  methadone dosing 
during pregnancy is recommended, especially during the 
third trimester when methadone metabolism and clearance 
are increased and dose augmentation is required.120,121 
Pregnant women should receive the methadone dose 
that is required for their opioid dependence, because 
the literature reports inconsistent results regarding the 
association between maternal methadone dose and severity 
of  neonatal withdrawal. Prenatal discussion with the 
methadone prescribing physician is recommended to plan 
for intrapartum methadone dosing.
Any regular, daily antenatal opioid exposure (e.g., morphine, 
codeine, oxycodone, methadone, or buprenorphine) can 
produce neonatal withdrawal, also known as neonatal 
abstinence syndrome. Estimates show that up to 96% 
of  infants display withdrawal symptoms, and a smaller 
proportion require pharmacotherapy.4,68,116,117,120,121 NAS 
is characterized by respiratory, gastrointestinal, central 
nervous system, and autonomic symptoms (Table 6). Onset 
of  withdrawal symptoms is dependent on the opiate’s half-
life; the longer the half-life, the later the onset of  withdrawal. 
Heroin-exposed infants may demonstrate symptoms within 
24 hours of  birth. In comparison, methadone-maintained 
infants have a delayed presentation at more than 24 hours, 
usually within 48 to 72 hours after birth and at up to 
4 weeks of  age.122 The length of  monitoring is based on 
Table 5. Management of withdrawal
Substance Management recommendation
Alcohol • Thiamine 100 mg po od × 3 days, folic acid 5 mg po od
• Diazepam 20 mg po q1–2h until minimal symptoms
• Use lorazepam 2–4 mg sl/po q2–4h prn during labour
• Monitor hydration status and electrolyte levels
High-dose benzodiazepines • Start at 2/3–3/4 of diazepam equivalent dose
• Taper by 10% per day
Opioids • Offer symptomatic therapy including gravol for nausea and vomiting, acetaminophen/
NSAIDs for myalgias
• Consider methadone or buprenorphine initiation
• Can use morphine 5–10 mg po q4–6h prn if methadone is not available
NSAIDs: non-steroidal anti-inflammatories
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the specific drug exposure. Treated neonatal withdrawal 
has not been associated with any long-term complications.
A variety of  standards of  practice have been documented 
in Canadian hospitals with variability by region and 
practitioner. Little research is available to validate current 
practices. Several scoring scales have been developed 
for evaluation of  NAS and response to therapy. The 
Finnegan scoring tool (also known as the Finnegan 
Neonatal Abstinence Scoring System) is the method 
most commonly used by Canadian hospitals.123 Non-
pharmacologic therapy is the standard of  care for all 
opioid-exposed infants.124 For a smaller subset of  infants, 
pharmacotherapy may be needed to treat severe symptoms. 
Opioid agonist medications are the most effective agents 
for treatment of  NAS.122,125 Options include morphine, 
methadone, and diluted tincture of  opium (contains small 
amount of  alcohol). Morphine is the most frequently used 
medication.122,123 Phenobarbital may be used as an adjunct 
to treat infants who are not well-controlled using an opioid 
alone. One half  of  Canadian hospitals care for substance-
exposed infants in the neonatal care unit or special care 
nursery. The other half  provide care for asymptomatic 
infants with the mother as part of  rooming-in. One 
retrospective cohort study demonstrated that rooming-
in, under the care of  supportive nursing and medical 
staff, was associated with decreased rates and length of  
morphine treatment, decreased need for admission to an 
NICU, decreased mean neonatal length of  stay in hospital, 
and increased likelihood of  discharge in the custody of  
the mother.126 Additional large-scale prospective studies 
are required to determine the optimal management of  
neonatal withdrawal.
Buprenorphine
Buprenorphine represents an alternative opioid replacement 
treatment. Buprenorphine is a partial agonist with a ceiling 
effect. It has typical opioid effects with less sedation than 
methadone and a threshold after which a higher dose has no 
further effect, thereby reducing the risk of  overdose on this 
medication.127 The main rationale for buprenorphine use 
for treating opioid dependence during pregnancy is reports 
of  reduced incidence and severity of  NAS128–131; however, 
there are limited data regarding the long-term effects of  
in utero exposure to buprenorphine.132,133 Buprenorphine 
should be prescribed by a physician who has experience with 
substitution treatment for opioid dependence. The only 
preparation of  buprenorphine readily available in Canada 
is Suboxone, which is a combination of  buprenorphine 
and naloxone. There is limited information on the safety 
of  this medication in pregnancy; therefore, the use of  
buprenorphine as a single agent (Subutex) is recommended 
during pregnancy. The availability of  buprenorphine during 
pregnancy is limited through Health Canada’s Special 
Access Program.
OPIOIDS FOR CHRONIC NON-CANCER PAIN
Pregnant women with a history of  chronic pain need to be 
managed according to evidence-based recommendations 
for chronic non-cancer pain.134,135 The goal of  therapy is 
to use the lowest effective dose of  scheduled controlled-
release opioids.134 Most women who use opioids for chronic 
non-cancer pain are not psychologically dependent on these 
medications. Risk factors for dependence on prescription 
opioids include past history of  drug dependence and 
psychiatric comorbid conditions such as posttraumatic 
stress disorder and eating disorders. Regular opioid use 
for pain management during pregnancy is associated 
with neonatal withdrawal.136,137 Methadone is the first-line 
treatment for chronic non-cancer pain and concurrent 
opioid dependence.
Recommendations
7. Methadone maintenance treatment should be standard 
of  care for opioid-dependent women during pregnancy. 
(II-IA) Other slow-release opioid preparations may be 
considered if  methadone is not available. (II-2B)
8. Opioid detoxification should be reserved for selected 
women because of  the high risk of  relapse to opioids. 
(II-2B)
9. Opiate-dependent women should be informed that 
neonates exposed to heroin, prescription opioids, 
methadone, or buprenorphine during pregnancy are 
monitored closely for symptoms and signs of  neonatal 
withdrawal (neonatal abstinence syndrome). (II-2B) 
Hospitals providing obstetric care should develop a 
protocol for assessment and management of  neonates 
exposed to opiates during pregnancy. (III-B)
Table 6. Neonatal abstinence syndrome
System Symptoms and signs
Respiratory Respiratory distress
Central nervous system Increased tone, tremors, seizure
Gastrointestinal Poor feeding, vomiting, regurgitation, 
diarrhea
Autonomic Sweating
APRIL JOGC AVRIL 2011  l  377
Substance Use in Pregnancy
PERIPARTUM PAIN MANAGEMENT
Women with substance use disorders, especially those 
with opioid dependence, face numerous peripartum 
pain management challenges, including increased pain 
sensitivity, inadequate analgesia, difficult intravenous 
access, and anxiety about suffering pain due to their history 
of  addiction.138–142 Inappropriate pain management is more 
likely than provision of  opioid analgesics for treatment of  
acute pain to lead to a relapse. Women on MMT should 
be continued on the same dose of  methadone, although 
this is ineffective for acute pain management.138,142 Opioids 
have been found to be safe and effective even in opioid-
dependent women; however, these women may require 
higher doses and more frequent analgesics for pain 
relief.138,142,143 Epidural analgesia is an ideal choice for pain 
management for opioid-dependent women. Agonist-
antagonist medications (e.g., butorphanol, nalbuphine, 
and pentazocine) should not be used in opioid-dependent 
individuals because of  the risk of  precipitating acute 
withdrawal. For more complicated cases (e.g., poor venous 
access, contraindications to epidural), referral to an 
anaesthesiologist should be arranged antenatally to discuss, 
in advance, alternatives for pain management.
Recommendation
10. Antenatal planning for intrapartum and postpartum 
analgesia may be offered for all women in consultation 
with appropriate health care providers. (III-B)
MANAGEMENT OF OPIOID OVERDOSE
Education about prevention of  opioid overdose should 
also be provided routinely. This includes advising patients 
that they could overdose if  they suddenly stop or markedly 
reduce their opioid medication and then resume their usual 
dose. They are also at risk of  overdose if  they combine 
opioids with other sedatives, such as benzodiazepines. 
They should be warned never to give or sell their opioid 
medication to anyone else, because others may lack 
tolerance to opioids. Finally, they should be advised 
to contact a physician immediately at the first signs of  
overdose (“nodding off,” slurred speech, drowsiness).
Acute opioid overdose during pregnancy can be managed 
with respiratory support and the use of  naloxone, a short-
acting opioid antagonist, as a last resort after an airway has 
been established. The dose of  naloxone should be based on 
response to treatment and duration of  action of  ingested 
opioid. Naloxone may be required on a continuous basis 
until the effects of  the opioid have diminished. Care should 
be taken to prevent acute withdrawal symptoms, which 
can cause fetal distress.144 On the basis of  gestational age 
and viability, the fetus should be monitored throughout 
treatment. Similarly, during neonatal resuscitation, naloxone 
should not be administered to a newborn of  an opioid-
dependent mother because of  the risk of  precipitating 
acute withdrawal and seizures.
POSTPARTUM CARE
Substance-using women require additional supports from 
health care professionals in the postpartum period. More 
frequents visits may be required to deal with their complex 
medical and psychosocial needs. Areas to review include 
the following:
• Support of  breastfeeding, as appropriate (see 
paragraph below for more details)
• Follow-up of  other medical problems such as liver 
disease and sexually transmitted infections
• Discussion of  contraceptive needs
• Surveillance and appropriate referral for treatment of  
postpartum mood and anxiety disorders
• Assessment of  substance use and encouragement to 
continue attending drug treatment programs
• Support with child protection services involvement
• Assistance with referrals for ongoing primary care and 
social services
BREASTFEEDING
Although there are numerous benefits of  breastfeeding, 
alcohol and illicit substances that are commonly abused 
(e.g., marijuana, cocaine, amphetamines) have been detected 
in breast milk.145–148 There have been reports documenting 
neonatal effects due to breast milk exposure; therefore, the 
decision to breastfeed should be made on an individual basis 
after discussing the potential risks and benefits.146,147149,150 
Breastfeeding may be delayed after maternal use of  any of  
these agents and any neonatal exposure to any fumes in 
the environment. Women who are regular substance users 
should be encouraged to remain abstinent while nursing 
and counselled regarding the increased risks for neonatal effects.
All opiates have been documented in breast milk in 
small amounts and are unlikely to be of  any clinical 
significance.106,121,151–157 Specifically, the presentation 
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and treatment of  neonatal withdrawal is not affected by 
exposure to methadone or buprenorphine in breast milk. 
Therefore, maternal opiate use is considered compatible 
with breastfeeding.
Codeine should be used with caution by women who 
are breastfeeding. Neonatal toxicity symptoms and signs 
such as drowsiness, apnea, and bradycardia have been 
demonstrated in women who have been prescribed codeine 
and who have a genetic predisposition to convert codeine 
to morphine at a faster rate (i.e., CYP2D6 ultrarapid 
metabolizers).158,159 Symptoms and signs worsen after 4 days 
of  codeine use, and alternate pain management should be 
considered after that time.160
Recommendation
11. The risks and benefits of  breastfeeding should be 
weighed on an individual basis because methadone 
maintenance therapy is not a contraindication to 
breastfeeding. (II-3B)
CONCLUSION
Problematic substance use in pregnancy is prevalent in 
the Canadian population. Perinatal health care providers 
can make a significant impact on improving pregnancy 
outcomes by providing non-judgemental supportive care 
within a harm reduction model to address substance 
use issues and social determinants of  health. Ongoing 
education in this area and development of  comprehensive 
care models are essential for the optimal care of  patients in 
these challenging circumstances.
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Addressograph
Antenatal psychosocial problems may be associated with unfavorable
postpartum outcomes. The questions on this form are suggested ways
of inquiring about psychosocial health. Issues of high concern to the
woman, her family or the caregiver usually indicate a need for
additional supports or services. When some concerns are identified,
follow-up and/or referral should be considered. Additional
information can be obtained from the ALPHA Guide. *Please consider
the sensitivity of this information before sharing it with other caregivers.
Antenatal Psychosocial
Health Assessment (ALPHA)
ANTENATAL FACTORS CONCERN COMMENTS / PLAN
FAMILY FACTORS
Social support (CA, WA, PD)
How does your partner/family feel about your pregnancy?
Who will be helping you when you go home with your baby?
Recent stressful life events (CA, WA, PD, PI)
What life changes have you experienced this year?
What changes are you planning during this pregnancy?
Couple’s relationship (CD, PD, WA, CA)
How would you describe your relationship with your partner?
What do you think your relationship will be like after the birth?
MATERNAL FACTORS
Prenatal care (late onset) (WA)
First prenatal visit in third trimester? (check records)
Prenatal education (refusal or quit) (CA)
What are your plans for prenatal classes?
Feelings toward pregnancy after 20 weeks (CA, WA)
How did you feel when you just found out you were pregnant?
How do you feel about it now?
Relationship with parents in childhood (CA)
How did you get along with your parents?
Did you feel loved by your parents?
Self esteem (CA, WA)
What concerns do you have about becoming/being a mother?
History of psychiatric/emotional problems (CA, WA, PD)
Have you ever had emotional problems?
Have you ever seen a psychiatrist or therapist?
Depression in this pregnancy (PD)
How has your mood been during this pregnancy?
ASSOCIATED POSTPARTUM OUTCOMES
The antenatal factors in the left column have been shown to be associated with the postpartum outcomes listed
below. Bold, Italics indicates good evidence of association. Regular text indicates fair evidence of association.
CA – Child Abuse   CD – Couple Dysfunction   PI – Physical Illness   
PD – Postpartum Depression   WA – Woman Abuse
Low
Some
High
Low
Some
High
Low
Some
High
Low
Some
High
Low
Some
High
Low
Some
High
Low
Some
High
Low
Some
High
Low
Some
High
Low
Some
High
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ANTENATAL FACTORS CONCERN COMMENTS /PLAN
SUBSTANCE USE
Alcohol/drug abuse (WA, CA) (1 drink=11/2 oz liquor, 12 oz beer, 5 oz wine)
How many drinks of alcohol do you have per week?
Are there times when you drink more than that?
Do you or your partner use recreational drugs?
Do you or your partner have a problem with alcohol or drugs?
Consider CAGE (Cut down, Annoyed, Guilty, Eye opener)
FAMILY VIOLENCE
COMMENTS:
Date Completed Signature
© ALPHA Group, April, 2005; Department of Family & Community Medicine, University of Toronto 
http://dfcm19.med.utoronto.ca/research/alpha
Low
Some
High
Low
Some
High
Low
Some
High
Low
Some
High
Low
Some
High
Current or past woman abuse (WA, CA, PD)
How do you and your partner solve arguments?
Do you ever feel frightened by what your partner says or does?
Have you ever been hit/pushed/slapped by a partner?
Has your partner ever humiliated you or psychologically abused you in
other ways?
Have you ever been forced to have sex against your will?
Woman or partner experienced or witnessed abuse
(physical, emotional, sexual) (CA,WA)
What was your parents’ relationship like?
Did your father ever scare or hurt your mother?
Did your parents ever scare or hurt you?
Were you ever sexually abused as a child?
Previous child abuse by woman or partner (CA)
Do you/your partner have children not living with you? 
If so, why?
Have you ever had involvement with a child protection agency
(ie. Children’s Aid Society)?
Child discipline (CA)
How were you disciplined as a child?
How do you think you will discipline your child?
How do you deal with your kids at home when they misbehave?
FOLLOW UP PLAN
 Supportive counselling by provider
 Additional prenatal appointments
 Additional postpartum appointments
 Additional well baby visits
 Public Health referral
 Prenatal education services
Nutritionist
 Community resources / mothers’ group
Homecare
 Parenting classes / parents’ support group
 Addiction treatment programs
 Smoking cessation resources
 Social Worker
 Psychologist / Psychiatrist
 Psychotherapist / marital / family therapist
 Assaulted women’s helpline / shelter / counseling
 Legal advice
 Children’s Aid Society
Other:
Other:
Other:
Other:
Used with permission.
